Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.

<h4>Aim</h4>Combination therapy with gemcitabine and nanoparticle albumin-bound paclitaxel (nab-paclitaxel), known as GnP therapy, significantly prolongs the survival of pancreatic cancer patients compared with gemcitabine monotherapy. However, it may cause severe neutropenia, requiring...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Genta Ito, Kazuyoshi Kawakami, Takeshi Aoyama, Takashi Yokokawa, Masashi Nakamura, Masato Ozaka, Naoki Sasahira, Masayuki Hashiguchi, Hayato Kizaki, Toshihiro Hama, Satoko Hori
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cc96a8ba7c564820827eaff691150d08
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc96a8ba7c564820827eaff691150d08
record_format	dspace
spelling	oai:doaj.org-article:cc96a8ba7c564820827eaff691150d082021-12-02T20:07:00ZRisk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.1932-620310.1371/journal.pone.0254726https://doaj.org/article/cc96a8ba7c564820827eaff691150d082021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0254726https://doaj.org/toc/1932-6203<h4>Aim</h4>Combination therapy with gemcitabine and nanoparticle albumin-bound paclitaxel (nab-paclitaxel), known as GnP therapy, significantly prolongs the survival of pancreatic cancer patients compared with gemcitabine monotherapy. However, it may cause severe neutropenia, requiring discontinuation of treatment. This study aimed to clarify the risk factors for Grade 3/4 neutropenia during GnP therapy.<h4>Methods</h4>Clinical data of pancreatic cancer patients who underwent GnP therapy at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research from December 2014 to December 2016 were retrospectively collected. The relationship of Grade 3/4 neutropenia onset to laboratory values and patient background factors was investigated by multivariate logistic regression analysis.<h4>Results</h4>Clinical data of 222 patients were analyzed. Grade 3/4 neutropenia occurred in 118 patients (53.2%) in the first cycle of GnP therapy. Multivariate analysis identified low absolute neutrophil count (ANC), high total bilirubin (T-Bil), and low C-reactive protein (CRP) as risk factors for Grade 3/4 neutropenia. Age was not a risk factor. The incidence of neutropenia was 85.7% in patients with all three risk factors, but only 27.7% in patients with none of them.<h4>Conclusion</h4>Low ANC, high T-Bil, and low CRP may be risk factors for Grade 3/4 neutropenia in patients receiving GnP therapy, even if these laboratory values are within normal reference ranges. Patients with these risk factors should be carefully monitored for adverse events.Genta ItoKazuyoshi KawakamiTakeshi AoyamaTakashi YokokawaMasashi NakamuraMasato OzakaNaoki SasahiraMasayuki HashiguchiHayato KizakiToshihiro HamaSatoko HoriPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 7, p e0254726 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Genta Ito Kazuyoshi Kawakami Takeshi Aoyama Takashi Yokokawa Masashi Nakamura Masato Ozaka Naoki Sasahira Masayuki Hashiguchi Hayato Kizaki Toshihiro Hama Satoko Hori Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
description	<h4>Aim</h4>Combination therapy with gemcitabine and nanoparticle albumin-bound paclitaxel (nab-paclitaxel), known as GnP therapy, significantly prolongs the survival of pancreatic cancer patients compared with gemcitabine monotherapy. However, it may cause severe neutropenia, requiring discontinuation of treatment. This study aimed to clarify the risk factors for Grade 3/4 neutropenia during GnP therapy.<h4>Methods</h4>Clinical data of pancreatic cancer patients who underwent GnP therapy at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research from December 2014 to December 2016 were retrospectively collected. The relationship of Grade 3/4 neutropenia onset to laboratory values and patient background factors was investigated by multivariate logistic regression analysis.<h4>Results</h4>Clinical data of 222 patients were analyzed. Grade 3/4 neutropenia occurred in 118 patients (53.2%) in the first cycle of GnP therapy. Multivariate analysis identified low absolute neutrophil count (ANC), high total bilirubin (T-Bil), and low C-reactive protein (CRP) as risk factors for Grade 3/4 neutropenia. Age was not a risk factor. The incidence of neutropenia was 85.7% in patients with all three risk factors, but only 27.7% in patients with none of them.<h4>Conclusion</h4>Low ANC, high T-Bil, and low CRP may be risk factors for Grade 3/4 neutropenia in patients receiving GnP therapy, even if these laboratory values are within normal reference ranges. Patients with these risk factors should be carefully monitored for adverse events.
format	article
author	Genta Ito Kazuyoshi Kawakami Takeshi Aoyama Takashi Yokokawa Masashi Nakamura Masato Ozaka Naoki Sasahira Masayuki Hashiguchi Hayato Kizaki Toshihiro Hama Satoko Hori
author_facet	Genta Ito Kazuyoshi Kawakami Takeshi Aoyama Takashi Yokokawa Masashi Nakamura Masato Ozaka Naoki Sasahira Masayuki Hashiguchi Hayato Kizaki Toshihiro Hama Satoko Hori
author_sort	Genta Ito
title	Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
title_short	Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
title_full	Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
title_fullStr	Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
title_full_unstemmed	Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
title_sort	risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/cc96a8ba7c564820827eaff691150d08
work_keys_str_mv	AT gentaito riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy AT kazuyoshikawakami riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy AT takeshiaoyama riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy AT takashiyokokawa riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy AT masashinakamura riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy AT masatoozaka riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy AT naokisasahira riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy AT masayukihashiguchi riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy AT hayatokizaki riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy AT toshihirohama riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy AT satokohori riskfactorsforsevereneutropeniainpancreaticcancerpatientstreatedwithgemcitabinenabpaclitaxelcombinationtherapy
_version_	1718375329123270656

Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.

Ejemplares similares